Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.
Here, Paul Paik of the Memorial Sloan Kettering Cancer Center, New York, NY discusses the development of treatments for squamous cell lung cancer and the importance of identifying new targets such as NFA202. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.
We use cookies to provide the best experience on our website. We also use third party cookies to collect analytical data and better improve our marketing strategies. If you continue to use this site you are consenting to the use of these cookies. For more information view our Cookie Policy.